UK markets closed

Iovance Biotherapeutics, Inc. (0JDK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
11.73+0.23 (+1.96%)
At close: 06:58PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.59
52-week change 3120.34%
S&P500 52-week change 322.36%
52-week high 318.31
52-week low 33.22
50-day moving average 311.04
200-day moving average 37.44

Share statistics

Avg vol (3-month) 353.27k
Avg vol (10-day) 329.45k
Shares outstanding 5123.17M
Implied shares outstanding 6N/A
Float 8210.9M
% held by insiders 10.57%
% held by institutions 189.24%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-25,156.85%

Management effectiveness

Return on assets (ttm)-39.86%
Return on equity (ttm)-81.91%

Income statement

Revenue (ttm)1.19M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -449.01M
Net income avi to common (ttm)-444.04M
Diluted EPS (ttm)-2.30
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)279.87M
Total cash per share (mrq)1
Total debt (mrq)75.86M
Total debt/equity (mrq)12.98%
Current ratio (mrq)2.79
Book value per share (mrq)2.28

Cash flow statement

Operating cash flow (ttm)-361.82M
Levered free cash flow (ttm)-211.47M